Full Press Release Details
REGENERON’S VEGF TRAP DEMONSTRATES POSITIVE PRELIMINARY RESULTS FROM SINGLE-AGENT PHASE 1 TRIAL IN PATIENTS WITH ADVANCED CANCER Results Presented at ASCO Annual Meeting on May 16, 2005.
REGN
REGENERON’S VEGF TRAP DEMONSTRATES POSITIVE PRELIMINARY RESULTS FROM SINGLE-AGENT PHASE 1 TRIAL IN PATIENTS WITH ADVANCED CANCER Results Presented at ASCO Annual Meeting on May 16, 2005
Key Takeaway: REGENERON’S VEGF TRAP DEMONSTRATES POSITIVE PRELIMINARY RESULTS FROM SINGLE-AGENT PHASE 1 TRIAL IN PATIENTS WITH ADVANCED CANCER Results Presented at ASCO Annual Meeting on May 16, 2005
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema